Edwards Lifesciences Corp (EW) : Renaissance Technologies scooped up 548,000 additional shares in Edwards Lifesciences Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 2,213,800 shares of Edwards Lifesciences Corp which is valued at $251,487,680.Edwards Lifesciences Corp makes up approximately 0.46% of Renaissance Technologies’s portfolio.
Other Hedge Funds, Including , Deimos Asset Management added EW to its portfolio by purchasing 10,000 company shares during the most recent quarter which is valued at $1,136,000. Edwards Lifesciences Corp makes up approx 0.95% of Deimos Asset Management’s portfolio.Ameritas Investment Partners boosted its stake in EW in the latest quarter, The investment management firm added 128 additional shares and now holds a total of 21,434 shares of Edwards Lifesciences Corp which is valued at $2,434,902. Edwards Lifesciences Corp makes up approx 0.16% of Ameritas Investment Partners’s portfolio.Columbus Circle Investors boosted its stake in EW in the latest quarter, The investment management firm added 33,790 additional shares and now holds a total of 2,209,825 shares of Edwards Lifesciences Corp which is valued at $250,505,762. Edwards Lifesciences Corp makes up approx 2.40% of Columbus Circle Investors’s portfolio. Wealth Enhancement Advisory Services added EW to its portfolio by purchasing 13,005 company shares during the most recent quarter which is valued at $1,489,333. Edwards Lifesciences Corp makes up approx 0.26% of Wealth Enhancement Advisory Services’s portfolio.
Edwards Lifesciences Corp opened for trading at $115.19 and hit $116.86 on the upside on Monday, eventually ending the session at $116.1, with a gain of 0.73% or 0.84 points. The heightened volatility saw the trading volume jump to 7,10,004 shares. Company has a market cap of $24,715 M.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.